Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical giant Gilead Sciences
So what: Gilead's gains today are all about the data released last night revolving around GS-7977. The study found that when the GS-7977 pill was combined with ribavirin, 100% of genotype 1 hep-C patients had no trace of the virus found after four weeks of treatment. Gilead also reported fourth-quarter results, which showed revenue grew by 10% to $2.2 billion, slightly beating consensus estimates of $2.18 billion, but earnings fell $0.08 shy of Wall Street's estimates ($0.97 vs. $1.05). Outside of the hep-C data, the highlight of Gilead's report was the 11% growth in its HIV drug, Atripla.
Now what: Today's data looks like bad news for much of the hep-C sector because, as of now, Gilead's drug looks far superior. That's the reason Idenix Pharmaceuticals
Craving more input? Start by adding Gilead Sciences to your free and personalized watchlist, so you can keep track of the latest news with the company.